Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Davies M, Osborne V, Lane S, Roy D, et al. Drug Saf 2020;43:645-656.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Davies M, Osborne V, Lane S, Roy D, et al. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Drug Saf 2020;43:645-656.
PMID: 32468196